Cargando…

Oncolytic virus-derived type I interferon restricts CAR T cell therapy

The application of adoptive T cell therapies, including those using chimeric antigen receptor (CAR)-modified T cells, to solid tumors requires combinatorial strategies to overcome immune suppression associated with the tumor microenvironment. Here we test whether the inflammatory nature of oncolytic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evgin, Laura, Huff, Amanda L., Wongthida, Phonphimon, Thompson, Jill, Kottke, Tim, Tonne, Jason, Schuelke, Matthew, Ayasoufi, Katayoun, Driscoll, Christopher B., Shim, Kevin G., Reynolds, Pierce, Monie, Dileep D., Johnson, Aaron J., Coffey, Matt, Young, Sarah L., Archer, Gary, Sampson, John, Pulido, Jose, Perez, Luis Sanchez, Vile, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314766/ https://www.ncbi.nlm.nih.gov/pubmed/32581235 http://dx.doi.org/10.1038/s41467-020-17011-z

Ejemplares similares

Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity
por: Schuelke, Matthew R., et al.
Publicado: (2019)

APOBEC3 Mediates Resistance to Oncolytic Viral Therapy
por: Huff, Amanda L., et al.
Publicado: (2018)

Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors
por: Wongthida, Phonphimon, et al.
Publicado: (2020)

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
por: Kottke, Timothy, et al.
Publicado: (2021)

APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy
por: Driscoll, Christopher B., et al.
Publicado: (2020)

Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?
por: Evgin, Laura, et al.
Publicado: (2021)

Single-Cycle Viral Gene Expression, Rather Than Progressive Replication and Oncolysis, Is Required for VSV Therapy of B16 Melanoma
por: Galivo, Feorillo, et al.
Publicado: (2009)

Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9
por: Eckert, Elizabeth C., et al.
Publicado: (2019)

Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy
por: Ilett, Elizabeth, et al.
Publicado: (2016)

Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas
por: Monie, Dileep D., et al.
Publicado: (2021)

Broad Antigenic Coverage Induced by Viral cDNA Library-based Vaccination Cures Established Tumors
por: Kottke, Timothy, et al.
Publicado: (2011)

Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses
por: Webb, Mason J., et al.
Publicado: (2023)

Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic Virotherapy
por: Vile, Richard, et al.
Publicado: (2023)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

LOCL-03 INTRATUMORAL DELIVERY OF CONDITIONALLY REPLICATIVE HUMAN ADENOVIRUS 657 EXPRESSING THE IMMUNE CO-STIMULATOR CD40L (CRAD657-CD40L) AS A POTENTIALLY PROMISING TREATMENT FOR RECURRENT PEDIATRIC HIGH GRADE GLIOMA
por: Webb, Mason, et al.
Publicado: (2022)

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
por: Annels, Nicola E., et al.
Publicado: (2020)

Oncolytic viruses: Narcissistic or altruistic arsonists?
por: Kendall, Luke, et al.
Publicado: (2023)

Immunogenicity of self tumor associated proteins is enhanced through protein truncation
por: Kottke, Tim, et al.
Publicado: (2016)

Prospects for combined use of oncolytic viruses and CAR T-cells
por: Ajina, Adam, et al.
Publicado: (2017)

Deciphering the biology of porcine epidemic diarrhea virus in the era of reverse genetics
por: Teeravechyan, Samaporn, et al.
Publicado: (2016)

Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma
por: Webb, Mason J., et al.
Publicado: (2023)

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion
por: Cockle, Julia V., et al.
Publicado: (2017)

Aptamer-facilitated Protection of Oncolytic Virus from Neutralizing Antibodies
por: Muharemagic, Darija, et al.
Publicado: (2014)

Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses
por: Ungerechts, Guy, et al.
Publicado: (2016)

In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion
por: Wongthida, Phonphimon, et al.
Publicado: (2016)

Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail
por: Tritz, Zachariah P, et al.
Publicado: (2021)

A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses
por: Smith, Katherine E. R., et al.
Publicado: (2023)

The oncolytic effects of reovirus in canine solid tumor cell lines
por: IGASE, Masaya, et al.
Publicado: (2015)

Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors
por: Schuelke, Matthew R, et al.
Publicado: (2022)

CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
por: Guedan, Sonia, et al.
Publicado: (2018)

Role of Memory T Cells in Allograft Rejection and Tolerance
por: Benichou, Gilles, et al.
Publicado: (2017)

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway
por: Twigger, Katie, et al.
Publicado: (2012)

Oncolytic Reovirus in Canine Mast Cell Tumor
por: Hwang, Chung Chew, et al.
Publicado: (2013)

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
por: Harrington, K.J., et al.
Publicado: (2010)

AN OPTIMIZED MOUSE PARABIOSIS PROTOCOL FOR INVESTIGATION OF AGING AND REJUVENATIVE MECHANISMS
por: Rodriguez, Sonia, et al.
Publicado: (2022)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
por: Jennings, VA, et al.
Publicado: (2014)

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
por: Samson, Adel, et al.
Publicado: (2018)

Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors
por: Rosewell Shaw, Amanda, et al.
Publicado: (2021)

Growth Associated Protein 43 (GAP-43) as a Novel Target for the Diagnosis, Treatment and Prevention of Epileptogenesis
por: Nemes, Ashley D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l5u0incfnlqkmjsga60ahd4ttt